Search

Objective: To identify early clinical predictors of sustained DAF status in patients with relapsing-remitting multiple sclerosis (RRMS) treated with Interferon Beta (IFN) and Glatiramer Acetate (GA). Background The novel concept of sustained disease activity free (DAF) status could be a viable goal of therapy based on clinical and radiological measures, yet applicable to immunomodulators currently in use. Design/Methods: DAF status was defined as absence of gadolinium-enhancing lesions, new/enlarging T2 lesions, confirmed relapses and 3-month confirmed disability progression. We assessed clinical predictors and their potential influence on the proportion of DAF patients receiving IFN and GA therapies in the long term. Categorical predictors based on baseline data were age (≤40 or >40 years), disease duration previous treatment ( 10 years), number of relapses in the previous 12 months (≤1 or ≥2), basal EDSS score (≤3.0 or ≥3.5), and treatment duration (years). Patients subgroups were stratified by baseline demographic and disease characteristics. Results: This is a retrospective, observational study of 245 naive and RRMS patients who received immunomodulators over 10 ( 9.77±3.28) years of follow up. Freedom from clinical and radiological activity was observed in 26 (28.3%) of 92 patients taking IFN and 40 (37%) of 108 taking GA ([OR]0.67, 95% CI 0.36–1.21; p=0.18). After multivariate analysis we found that the only independent predictive factor for DAF status was Conclusions: Both IFN and GA induced DAF status in patients with RRMS, sustained in the long term. Early treatment initiation could be an important predictor of that status. Disclosure: Dr. Rojas has nothing to disclose. Dr. Vrech has nothing to disclose. Dr. Rojas has nothing to disclose. Dr. Rojas has nothing to disclose. Dr. Carra has nothing to disclose.

Objective: To examine the effects of Interferon beta (IFNb) and Glatiramer Acetate (GA) on sustained disease activity free (DAF) status. Background IFNb and GA provide similar levels of efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). However, they have not been demonstrated to induce disease remission. The sustained DAF status is a novel concept and viable goal of therapy based on clinical and radiological measures. Design/Methods: DAF status was defined as no activity on clinical measures (relapses and change in EDSS),and radiological measures (gadolinium-enhancing lesions and new/enlarging T2 lesions on cranial MRI). We assessed the impact of IFNb and GA on the proportion of DAF patients based on individual and combined components. All patients were matched according to baseline characteristics and treatment exposure. Results: This is a retrospective, observational study of 245 naive and RRMS patients who received immunomodulators over 10 (9.77+-3.28) years of follow up. 41 (35%) of 117 patients taking IFNb and 46 (35.9%) of 128 taking GA were free of clinical disease activity ([OR]0.96, 95% CI 0.56-1.62; p=0.8). 73 (77.7%) of 94 and 86 (81.9%) of 105 patients receiving IFNb and GA, respectively, were free of radiological disease activity ([OR]0.76 95% CI 0.38-1.53; p=0.45). Freedom from combined activity was observed in 26 (28.3%) of 92 patients taking IFNb and 40 (37%) of 108 taking GA ([OR]0.67, 95% CI 0.36-1.21; p=0.18). Although no differences were found between group treatments, subgroups analysis demonstrated a greater proportion of patients free from clinical disease activity among those on >=5 years of GA therapy ([OR] 0.32, 95% CI 0.12-0.82; p Conclusions: Both IFNb and GA induced DAF status in patients with RRMS, sustained in the long term. DAF status could be an important measure of therapeutic response in MS, yet applicable to immunomodulators currently in use. Disclosure: Dr. Carra has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Schering, Novartis, and Teva Neuroscience. Dr. Rojas has nothing to disclose. Dr. Vrech has nothing to disclose. Dr. Lindembaum has nothing to disclose.

Objective: To evaluate social cognition (SC) and theory of mind (TOM) in Huntington9s disease (HD). Background SC embraces several sub-domains related with the ability to predict what others will think, feel or do in novel situations. TOM is the core component of social functioning and relies on the ability to represent the mental states of others and to predict their possible behaviors. HD is characterized by involuntary movements and psychiatric, behavioral and cognitive dysfunctions. HD patients are often socially aloof, show lack of empathy, cognitive rigidity and mood disturbances. Design/Methods: After giving informed consent, 5 patients were diagnosed with HD by clinical findings and genetic testing and composed the sample of this study. The mean age was 47±22.2 years, the average duration of the illness was 7.4±10.5 years, and the mean CAG repeats in the expanded allele was 47, 8±10, 4. The mean level of education was 14, 4±2.6 years. An SC / TOM battery that included Wisconsin Card Sorting Test (WCST), Reading the Eyes in the Mind Test (REMT), Iowa Gambling Task (IGT), Faux Pas test (FPT) and reversion test was administered. All data were compared with control individuals.Statistical analysis was carried out using one-way ANOVA and correlation coefficients. Results: HD patients performed poorly as compared with control subjects in IGT and FPT, respectively (p Conclusions: The SC and TOM impairment in our HD patients agree with previously reported series and contribute to support a fronto-striatal involvement.Interestingly, in these patients an inverse correlation was observed among SC, TOM and nCAG repeats and disease duration, which may predict a more severe evolution of the disease. Disclosure: Dr. Etcheverry has nothing to disclose. Dr. Demey has nothing to disclose. Dr. Ruotolo has nothing to disclose. Dr. Leis has nothing to disclose. Dr. Orellano has nothing to disclose. Dr. Vanotti has nothing to disclose. Dr. Vilas has nothing to disclose. Dr. Villar has nothing to disclose. Dr. Rojas has nothing to disclose. Dr. Parisi has nothing to disclose. Dr. Persi has nothing to disclose. Dr. Allegri has nothing to disclose. Dr. Gatto has nothing to disclose.